SLAS Discovery Volume 33 showcases new innovations in drug discovery

Oak Brook, IL – Volume 33 of SLAS Discovery features one review, three original research articles and one entry in the upcoming Special Issue on Biomolecular Condensates as Targets for Drug Discovery.

Reviews

• Antimicrobial resistance: Linking molecular mechanisms to public health impact
  This review highlights how β-lactamases and efflux pumps, combined with mobile genetic elements, drive the rapid spread of multidrug-resistant (MDR) and extremely drug-resistant (XDR) pathogens, posing a serious threat to global health and agriculture.

Original Research

• Advancing the development of TRIP13 inhibitors: A high-throughput screening approach
  In this study, the researchers developed a high-throughput luminescence-based assay to screen for TRIP13 inhibitors, identifying anlotinib as a promising candidate. Their discovery presents a new approach for targeting TRIP13 in cancers that are resistant to therapy and deficient in retinoblastoma.
• Combinatorial screen with apoptosis pathway targeted agents alrizomadlin, pelcitoclax, and dasminapant in multi-cell type tumor spheroids
  This research assesses the effectiveness of apoptosis-targeting drugs—alrizomadlin, pelcitoclax and dasminapant—in solid tumor spheroids, both alone and in combination with other therapies. The results emphasize the potential of modifying the apoptosis pathway to improve cancer treatment in various aggressive solid tumors.
• The authors identify small-molecule inhibitors of hyperphosphorylated tau aggregation and neurotoxicity through a high-throughput screen, offering a promising new therapeutic strategy for Alzheimer’s disease and related tauopathies by directly targeting tau pathology.

Biomolecular Condensates as Targets for Drug Discovery

This upcoming Special Issue, guest edited by Charles P. Hart, PhD (University of California, San Francisco), will explore the role of biomolecular condensates in diseases and the potential for drug discovery by modulating their formation, stability or dissolution in neurodegenerative, cancer and inflammatory disorders.

• A biochemical screening platform to target chromatin states using condensates as a tool
  This study presents a novel drug discovery approach that targets dysfunctional chromatin states by leveraging their phase-separated condensate properties, enabling the identification of context-specific small-molecule modulators to reduce off-target effects and enhance therapeutic potential.

Access to this issue of SLAS Discovery is available at https://www.slas-discovery.org/issue/S2472-5552(25)X0004-6

*****

SLAS Discovery reports how scientists develop and use novel technologies and/or approaches to provide and characterize chemical and biological tools to understand and treat human disease. The journal focuses on drug discovery sciences with a strong record of scientific rigor and impact, reporting on research that:

• Enables and improves target validation
• Evaluates current drug discovery technologies
• Provides novel research tools
• Incorporates research approaches that enhance depth of knowledge and drug discovery success

SLAS (Society for Laboratory Automation and Screening) is an international professional society of academic, industry and government life sciences researchers and the developers and providers of laboratory automation technology. The SLAS mission is to bring together researchers in academia, industry and government to advance life sciences discovery and technology via education, knowledge exchange and global community building.

SLAS Discovery: Advancing the Science of Drug Discovery, 2024 Impact Factor 2.7. Editor-in-Chief Robert M. Campbell, Ph.D., Grove Biopharma, Inc., Chicago, IL (USA)

 

###

---

---